Health Care Cost

Lower-sodium oxybate (LXB) and sodium oxybate (SXB) were proven equally effective for cataplexy and excessive daytime sleepiness (EDS), despite LXB having 92% less sodium.

Qualitative interviews were conducted and a web-based quantitative survey was administered to have a clearer understanding of the economic impact of social determinants of health on patients living with generalized myasthenia gravis (gMG).

Updated vaccines are on their way to US pharmacies; importance of early diagnosis and treatment for individuals at risk of cardiovascular disease; Walgreens pharmacists stage their own protest.

Pinky, a mobile mammography unit from Stony Brook University Hospital Cancer Center on Long Island, increased screening for breast cancer from 9% to 69% among the predominantly Latina population that it serves.

Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.

Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health and the Allina Health Cancer Institute, discusses the successes and challenges of a population health reimbursement model and gives advice for other health organizations considering a similar partnership within their practices.

The data show the average age of dialysis in the least vulnerable neighborhoods was 68.2 years old, but 59.4 years—almost a decade earlier—in the most vulnerable.

Providers have to know how to manage patients who are hesitant to switch to a biosimilar and payers who have specific preferences about which biosimilar to use.

A presentation at the Association of Community Cancer Centers’ 40th National Oncology Conference explored how a cancer screening initiative can be sustainable and revenue positive while driving value-based savings in an evolving market.

Margaret Liang, MD, MSHPM, gynecologic oncologist and program director for the gynecologic oncology fellowship program at Cedars-Sinai Cancer Center, discusses the Association of Community Cancer Centers' Financial Advocacy Services guidelines, which focus on providing financial support to patients with cancer.

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, speaks on the unique perspectives and challenges smaller health care practices may face when entering into alternative payment models and shares key insights for addressing these issues.

The FDA has approved Tofidence, the first tocilizumab biosimilar in the United States, which will be used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).

Jennifer Sturgill, DO, Central Ohio Primary Care, discusses how shortages of antibiotics and medications for attention-deficit/hyperactivity disorder have affected primary care, as well as addresses the impact on heart failure care of CMS’ recent announcement of the first 10 drugs up for price negotiation in 2026 under the Inflation Reduction Act (IRA).

Major companies committed to joining Medicare drug price negotiations; Boehringer Ingelheim introduced a low-cost version of its adalimumab biosimilar; schools begin to stock naloxone amid rising opioid deaths among young people.

This year’s 40th National Oncology Conference from the Association of Community Cancer Centers (ACCC) will take place in Austin, Texas, from October 4-6, with content designed to reflect the theme of “Reimagining Innovation.”

In this interview from our recent Institute for Value-Based Medicine® event, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the positive impact that Choosing Wisely and enhanced recovery after surgery, or EROS, protocols have had on patients receiving treatment for breast cancer.

The October issue of Health Affairs examines the multifaceted aspects of structural racism in health care, exploring historical roots, policy implications, public biases, innovative solutions, and institutional challenges, urging action to confront and dismantle disparities.

Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.

A new grant aims to address maternal mortality in predominantly Black rural areas; Eli Lilly's drug to treat atopic dermatitis has not received FDA approval; a preliminary injunction is granted to Planned Parenthood South Atlantic.

Drug maker payments to ophthalmologists were associated with the choice of higher-cost therapies for age-related macular degeneration (AMD) that could increase Medicare costs, but biosimilars could help.

The number one ingredient that an oncology-based alternative payment model needs to succeed is collaboration, explained Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance (COA).

Employees want to know that their employers have a vested interest in their health, Vikki Walton, MBA, health equity leader at Mercer, explains.

Chemotherapy drug shortages put young patients at risk; restrictions and challenges cause concerns of a rise in teen births; at least 28 companies failed to prove sufficient product testing for cough syrups.

Adjuvant therapy, instead of just surgery alone, for early-stage non-small-cell lung cancer (NSCLC) after surgery incurs lower medical costs than surgery alone.